The abstract is read at the publisher; the summary is JClub's.
Metformin suppresses podocyte ferroptosis in murine diabetic nephropathy by inhibiting the MAPK14-SLC7A11-GPX4 axis, restoring GPX4/SLC7A11 and reducing lipid peroxidation.
- Why it matters: Podocyte loss drives diabetic nephropathy progression, but the dominant molecular mechanism and actionable therapeutic targets have been unclear.
- What they did: Using integrative multi-omics—snRNA-seq of 156,043 human kidney nuclei, spatial metabolomics, in vitro podocyte assays, and targeted urinary metabolomics—metformin was tested in db/db models and podocytes for effects on MAPK14-SLC7A11-GPX4 and fatty-acid dysregulation.
- The result: A urinary fatty-acid signature identified palmitoylcarnitine as a biomarker (AUC 0.974) linked with blood glucose, eGFR, serum creatinine, and blood urea nitrogen, supporting translational anti-ferroptosis diagnostics.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.